{"meta":{"query_hash":"ed313e58e88a","filters":{"venue":"Antibodies"},"cohort_total":14,"direct_labels_cover":0,"predictions_cover":14,"exported":14,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/ed313e58e88a","api":"https://metacan.xera.ac/api/v1/cohort?venue=Antibodies"},"results":[{"id":"W1981214889","doi":"10.3390/antib2020193","title":"In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments","year":2013,"lang":"en","type":"article","venue":"Antibodies","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"In vivo; Single-chain variable fragment; Computational biology; Monoclonal antibody; Antibody; Function (biology); Biology; Chemistry; Cell biology; Immunology; Genetics","score_opus":0.016858200710161978,"score_gpt":0.29309245986187277,"score_spread":0.2762342591517108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981214889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9193978,0.00085052685,0.0003266327,0.0028902735,0.00006648914,0.00082864263,0.00003327639,0.000027425724,0.07557894],"genre_scores_gemma":[0.96159863,0.00040030153,0.006362705,0.0007049719,0.00018067272,0.0001639645,0.000029146453,0.000022695907,0.030536888],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876857,0.000031665826,0.00032425116,0.00022012196,0.00031382294,0.00034157897],"domain_scores_gemma":[0.99932647,0.000101341975,0.00006706546,0.00025672666,0.00014585356,0.000102547885],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014610043,0.00013544502,0.0003202178,0.00019567477,0.00006942093,0.000016152706,0.0001323745,0.000076371325,0.0019751727],"category_scores_gemma":[0.000032839256,0.00010778358,0.00007142265,0.00031061954,0.0001888903,0.0001362685,0.000099739824,0.00014475164,0.0002515927],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014711358,0.0011866145,0.13608938,0.00070466497,0.00015675233,0.000028810797,0.0009412742,0.0000063787043,0.81024355,0.019424604,0.027238403,0.0038324762],"study_design_scores_gemma":[0.0037097347,0.0011282688,0.11678969,0.0008117398,0.000080325866,0.000112251546,0.002393502,0.00041445738,0.3136784,0.042875517,0.51723033,0.0007757688],"about_ca_topic_score_codex":0.0017886185,"about_ca_topic_score_gemma":0.000038900907,"teacher_disagreement_score":0.4965651,"about_ca_system_score_codex":0.00003175698,"about_ca_system_score_gemma":0.00005366746,"threshold_uncertainty_score":0.99893713},"labels":[],"label_agreement":null},{"id":"W2081902566","doi":"10.3390/antib3020205","title":"Engineered Bovine Antibodies in the Development of Novel Therapeutics, Immunomodulators and Vaccines","year":2014,"lang":"en","type":"article","venue":"Antibodies","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Canadian Food Inspection Agency; Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Antibody; Biology; Immunoglobulin light chain; Gene; Genetics; Computational biology","score_opus":0.03762164436213006,"score_gpt":0.31407926344770837,"score_spread":0.2764576190855783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081902566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940088,0.0022548689,0.00024615193,0.001627314,0.00006641425,0.00023073019,0.0000065230124,0.000019269537,0.0015399216],"genre_scores_gemma":[0.99490696,0.0006496397,0.0036457486,0.00027017223,0.000083753104,0.00000720236,0.00002283093,0.000015717203,0.0003979915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986977,0.00004450555,0.00041691063,0.00021127981,0.00032602387,0.0003036061],"domain_scores_gemma":[0.9992799,0.00025202084,0.00006917166,0.00024280399,0.000110608176,0.00004545779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005528069,0.00019931051,0.00039552298,0.00018787349,0.00011778347,0.000020856492,0.00016412565,0.000063106425,0.000015570798],"category_scores_gemma":[0.00007647163,0.0001181719,0.000067411085,0.00017693594,0.00016843945,0.00006450889,0.00009573218,0.00018705573,0.0000059525564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064028276,0.0007067761,0.79748744,0.0008918387,0.00043408014,0.000011846764,0.01150026,0.000011052678,0.14483857,0.0058395215,0.00026428857,0.037374023],"study_design_scores_gemma":[0.0011384572,0.00024699574,0.9696132,0.00018419404,0.000038521295,0.000042170956,0.00081359973,0.0009682689,0.015980301,0.0001152894,0.010686292,0.0001727421],"about_ca_topic_score_codex":0.00010377925,"about_ca_topic_score_gemma":0.000098744684,"teacher_disagreement_score":0.17212571,"about_ca_system_score_codex":0.000011073446,"about_ca_system_score_gemma":0.000056841716,"threshold_uncertainty_score":0.481891},"labels":[],"label_agreement":null},{"id":"W2615906896","doi":"10.3390/antib6020007","title":"Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function","year":2017,"lang":"en","type":"article","venue":"Antibodies","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Zymeworks (Canada)","funders":"Centers for Disease Control and Prevention","keywords":"Effector; Fragment crystallizable region; Antibody-dependent cell-mediated cytotoxicity; Protein engineering; Antibody; Epitope; Context (archaeology); Function (biology); Biology; Biophysics; Chemistry; Cell biology; Monoclonal antibody; Biochemistry; Genetics; Enzyme","score_opus":0.03435150278124715,"score_gpt":0.3166015176457345,"score_spread":0.28225001486448736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615906896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856593,0.002051608,0.0008375174,0.0018672395,0.0006269761,0.0009176288,0.00008061575,0.00015642318,0.007802661],"genre_scores_gemma":[0.9872437,0.00086621364,0.0030729368,0.00009364481,0.0008468766,0.000065472916,0.00011986919,0.000060204013,0.007631051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823993,0.000018137998,0.00025653493,0.0004561773,0.00043541938,0.0005937723],"domain_scores_gemma":[0.99848664,0.00026127268,0.00014268751,0.00062370644,0.0002985115,0.00018720132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002714122,0.00031802984,0.0005325312,0.00035909488,0.0008079759,0.0001971464,0.00024098517,0.00011072186,0.00004890474],"category_scores_gemma":[0.00042054104,0.00022184433,0.00021116695,0.00015174388,0.00024403234,0.00025879496,0.00011118383,0.00024911997,0.00014314365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013696505,0.00066367444,0.5732619,0.0044159447,0.0024619463,0.00037881732,0.00041530954,0.00004301139,0.27504414,0.007444818,0.04178521,0.08038871],"study_design_scores_gemma":[0.0023561346,0.002479434,0.85728353,0.0005240768,0.00024660578,0.00011457954,0.000068597554,0.00088539504,0.043615162,0.00008045352,0.0918749,0.0004711375],"about_ca_topic_score_codex":0.00012329464,"about_ca_topic_score_gemma":0.000027381979,"teacher_disagreement_score":0.28402162,"about_ca_system_score_codex":0.000041388863,"about_ca_system_score_gemma":0.00007351138,"threshold_uncertainty_score":0.9046549},"labels":[],"label_agreement":null},{"id":"W2765263172","doi":"10.3390/antib6040016","title":"Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy","year":2017,"lang":"en","type":"review","venue":"Antibodies","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund; Ligue Contre le Cancer; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Institute of Cancer Research; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Receptor; Cancer therapy; Cancer; Agonist; Tumor necrosis factor alpha; Cytokine; Antibody; Cancer cell; Biology; Cancer research; Computational biology; Immunology; Genetics","score_opus":0.07907894619068304,"score_gpt":0.3912741543676535,"score_spread":0.31219520817697044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765263172","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013432956,0.99753875,0.0001655544,0.00003697348,0.00019547196,0.0005172463,0.000078017576,0.000009261169,0.00011541188],"genre_scores_gemma":[0.0004320443,0.9965822,0.0008384985,0.000023565859,0.0004265581,0.00006862525,0.00030690062,0.000041504496,0.0012800911],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906635,0.00003453196,0.00022026534,0.00042273244,0.000054557422,0.00020158969],"domain_scores_gemma":[0.99939716,0.00002916904,0.00026943636,0.00020855325,0.000057769717,0.000037903174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014367778,0.00030411806,0.00065909734,0.00004650864,0.0003764073,0.00009399047,0.000107572654,0.0002562201,0.0000034488276],"category_scores_gemma":[0.0000484111,0.00021906878,0.00015440221,0.000015300111,0.00017530446,0.0000067777264,0.0001228111,0.000062450476,3.5843044e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010096782,0.00000883718,0.00011464333,0.0029275615,0.00023365801,7.4396917e-7,0.000067444445,1.1997541e-7,0.003253514,0.0001553447,0.0005656643,0.9926624],"study_design_scores_gemma":[0.00018173245,0.00008524257,0.00013060585,0.0012002155,0.00012040503,0.00000651624,0.000030197447,0.000005276768,0.0011999886,0.0001345265,0.9966057,0.00029957073],"about_ca_topic_score_codex":0.000021069902,"about_ca_topic_score_gemma":0.000019368345,"teacher_disagreement_score":0.99604005,"about_ca_system_score_codex":0.0000041775447,"about_ca_system_score_gemma":0.00005336651,"threshold_uncertainty_score":0.89333653},"labels":[],"label_agreement":null},{"id":"W2793145624","doi":"10.3390/antib7010009","title":"Structural Changes in Stx1 Engineering Monoclonal Antibody Improves Its Functionality as Diagnostic Tool for a Rapid Latex Agglutination Test","year":2018,"lang":"en","type":"article","venue":"Antibodies","topic":"Escherichia coli research studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Escherichia coli; Monoclonal antibody; Hybridoma technology; Linker; Microbiology; Recombinant DNA; Single-chain variable fragment; Diphtheria toxin; Antigen; Bacteria; Chemistry; Antibody; Shiga toxin; Dissociation constant; Toxin; Biology; Biochemistry; Gene","score_opus":0.015298842604272266,"score_gpt":0.3045175525882544,"score_spread":0.28921870998398214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793145624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725807,0.0013268528,0.00011064873,0.00044294138,0.00020164228,0.000422658,0.000066173016,0.00002265855,0.000148345],"genre_scores_gemma":[0.99739015,0.0007533304,0.0005209619,0.00010807364,0.00061475515,0.0000984955,0.00016857608,0.000019232779,0.00032642085],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989867,0.000026271964,0.0001622198,0.0003289925,0.00014561064,0.00035018817],"domain_scores_gemma":[0.999227,0.00025622256,0.00005673898,0.0001503774,0.00027231258,0.000037381928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022859253,0.00017435223,0.00016425528,0.00007112535,0.000145644,0.00003681492,0.00012404213,0.0000917107,0.000017163644],"category_scores_gemma":[0.00357717,0.00016043066,0.00005540146,0.000110518195,0.00010985633,0.000013463549,0.00015525564,0.00007919464,0.00000781687],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007512778,0.000035574638,0.05724069,0.000101165686,0.000069863556,0.0000021107246,0.0000904917,0.000012511955,0.9398917,0.0001805382,0.00034547842,0.001954755],"study_design_scores_gemma":[0.00067174743,0.0009899605,0.70412076,0.00004891274,0.000016948921,0.0000064557676,0.00007099153,0.0025532006,0.2859844,0.00012604847,0.0051066508,0.00030391925],"about_ca_topic_score_codex":0.00003100391,"about_ca_topic_score_gemma":0.000178558,"teacher_disagreement_score":0.6539073,"about_ca_system_score_codex":0.00002109181,"about_ca_system_score_gemma":0.000055991288,"threshold_uncertainty_score":0.65421724},"labels":[],"label_agreement":null},{"id":"W2931416517","doi":"10.3390/antib8020027","title":"Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases","year":2019,"lang":"en","type":"review","venue":"Antibodies","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada","funders":"","keywords":"Antibody; Medicine; Cerebrospinal fluid; Single-domain antibody; Central nervous system; Computational biology; Neuroscience; Immunology; Biology; Pathology","score_opus":0.1310407975241597,"score_gpt":0.4198972390929485,"score_spread":0.2888564415687888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2931416517","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012362091,0.9937834,0.000014125882,0.0006179614,0.00028166827,0.0025716068,0.00053759955,0.000033209188,0.00092419056],"genre_scores_gemma":[0.0005697719,0.9896686,0.00012784671,0.00013348815,0.000356224,0.00012969598,0.00030666243,0.0000807967,0.008626878],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977918,0.000113088514,0.00060667965,0.00053560705,0.0004126631,0.0005401152],"domain_scores_gemma":[0.9973057,0.0015647758,0.00029990825,0.0005421058,0.00014969832,0.00013782052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013803282,0.00061878393,0.0022072848,0.00023414214,0.00027978385,0.000067305395,0.00022616677,0.0001230091,0.000072176015],"category_scores_gemma":[0.000058272602,0.00031526168,0.0010601747,0.0001513881,0.0006412875,0.00006674178,0.000108608736,0.00014935296,0.000048974798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019472922,0.0005044193,0.004597753,0.022759076,0.0021367744,0.000044863886,0.00039270986,8.4839314e-8,0.000027527965,0.0008525533,0.0008819904,0.9676075],"study_design_scores_gemma":[0.00070110726,0.0010170046,0.0011935142,0.0053438544,0.0039866026,0.00014083905,0.00025459848,0.000018199455,0.000037196944,0.00031378624,0.9866848,0.00030848745],"about_ca_topic_score_codex":0.00014320994,"about_ca_topic_score_gemma":0.0000093275075,"teacher_disagreement_score":0.9858028,"about_ca_system_score_codex":0.00007847992,"about_ca_system_score_gemma":0.00024488402,"threshold_uncertainty_score":0.99992996},"labels":[],"label_agreement":null},{"id":"W2980125027","doi":"10.3390/antib8040050","title":"NR4A Expression by Human Marginal Zone B-Cells","year":2019,"lang":"en","type":"article","venue":"Antibodies","topic":"Nuclear Receptors and Signaling","field":"Neuroscience","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Expression (computer science); Marginal zone; Biology; Cell biology; Evolutionary biology; Genetics; Computer science","score_opus":0.016473522761831245,"score_gpt":0.25846053588750567,"score_spread":0.24198701312567442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980125027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855789,0.00007475496,0.000041858082,0.00007070991,0.00032459418,0.00009285158,0.000007820918,0.00007103222,0.0137375025],"genre_scores_gemma":[0.9832594,0.000061694336,0.00010581197,0.00028821052,0.00005545646,0.000001045522,0.0000027686392,0.000018765193,0.016206848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914855,0.00004458743,0.00011781673,0.00027424004,0.00019453857,0.00022024091],"domain_scores_gemma":[0.9996714,0.000047457077,0.00005190009,0.0001737132,0.000011654932,0.0000438631],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006978998,0.00010465907,0.00013218705,0.000037798785,0.00017965118,0.00006491764,0.00017366979,0.00004156343,0.0014400738],"category_scores_gemma":[0.00001232751,0.00008614334,0.000049572278,0.000061536695,0.00006258585,0.00015189975,0.000083701096,0.00010675813,0.0014314142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007613069,0.000036037083,0.0012170778,0.000012727415,9.808402e-7,0.0000036883853,0.00012566622,0.00000215102,0.97900003,0.00054102705,0.01874804,0.0003049629],"study_design_scores_gemma":[0.00019415471,0.000056058823,0.00011274668,0.000038392267,0.0000020697296,0.0000021359886,0.00006056083,0.000039709957,0.9326032,0.000085069674,0.06668571,0.000120245684],"about_ca_topic_score_codex":0.00001962623,"about_ca_topic_score_gemma":5.8897444e-7,"teacher_disagreement_score":0.047937665,"about_ca_system_score_codex":0.0000081875305,"about_ca_system_score_gemma":0.000004540046,"threshold_uncertainty_score":0.99947274},"labels":[],"label_agreement":null},{"id":"W3040981623","doi":"10.3390/antib9030032","title":"Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2","year":2020,"lang":"en","type":"review","venue":"Antibodies","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Internalization; Intracellular; Antibody-drug conjugate; Antibody; Drug; Cancer research; Medicine; Receptor; Monoclonal antibody; Biology; Pharmacology; Immunology; Cell biology; Internal medicine","score_opus":0.14169934982535706,"score_gpt":0.4447093743096557,"score_spread":0.3030100244842986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040981623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004372312,0.9934558,0.00004270483,0.00042624073,0.00012910823,0.0009869242,0.00017589718,0.00002758111,0.00038338904],"genre_scores_gemma":[0.004228846,0.9942944,0.00020219205,0.000068515685,0.0002326003,0.000012878659,0.00057805586,0.00005451104,0.00032800902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770325,0.00016546446,0.000903233,0.000400521,0.0005159926,0.00031152848],"domain_scores_gemma":[0.99791616,0.00069062744,0.0006664735,0.00037271742,0.00024408501,0.00010995793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035389495,0.0004070782,0.0019154794,0.00021037183,0.000110245455,0.000043329917,0.0003907232,0.00027051757,0.00008192562],"category_scores_gemma":[0.00020279778,0.00024304616,0.0004127495,0.0004593052,0.0005869672,0.0001293691,0.00040819077,0.00055939285,0.000021666676],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016156325,0.00012922358,0.0019983961,0.053772073,0.0011808358,0.000033232034,0.00049047207,2.3307867e-7,0.00554433,0.00027354326,0.000189212,0.9362269],"study_design_scores_gemma":[0.00043831384,0.00041955683,0.0007466382,0.008913238,0.0013030462,0.00006830039,0.00013619698,0.00027676037,0.0016638873,0.000049240505,0.9856142,0.00037066778],"about_ca_topic_score_codex":0.00039111325,"about_ca_topic_score_gemma":0.000007874272,"teacher_disagreement_score":0.98542494,"about_ca_system_score_codex":0.000023824794,"about_ca_system_score_gemma":0.00027661034,"threshold_uncertainty_score":0.9911135},"labels":[],"label_agreement":null},{"id":"W4388747498","doi":"10.3390/antib12040075","title":"Expanding the Anti-Phl p 7 Antibody Toolkit: An Anti-Idiotype Nanobody Inhibitor","year":2023,"lang":"en","type":"article","venue":"Antibodies","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Diamond Light Source; Medical Research Council Canada; Wellcome Trust","keywords":"Paratope; Immunoglobulin D; Antibody; Idiotype; Molecular biology; Immunoglobulin Idiotypes; Immunoglobulin Fab Fragments; Monoclonal antibody; Isotype; Recombinant DNA; Antigen; Hybridoma technology; Epitope; Biology; Chemistry; Virology; Immunology; Complementarity determining region; Genetics; B cell; Gene","score_opus":0.047802626321804834,"score_gpt":0.37914583691274695,"score_spread":0.3313432105909421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388747498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98403823,0.00128146,0.000017755125,0.006515011,0.00085632666,0.00057499955,0.00006284374,0.00047819925,0.006175169],"genre_scores_gemma":[0.9835849,0.0048359046,0.00018290807,0.0008060571,0.0015046651,0.000021541835,0.00045384356,0.0000804476,0.00852976],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964822,0.00017054853,0.0005425986,0.0006904583,0.0009958111,0.0011183668],"domain_scores_gemma":[0.99817723,0.00031946966,0.00012016801,0.0008027813,0.00026105845,0.00031927673],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008689187,0.00044086506,0.0007075231,0.00042662665,0.00097179256,0.0001879772,0.0004789423,0.00018990795,0.00031457716],"category_scores_gemma":[0.00024267072,0.00027857337,0.00031585444,0.0011350112,0.00057761243,0.0004014889,0.0003991275,0.0005858895,0.0015621724],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029827055,0.00030878806,0.4747285,0.0003795595,0.00035661727,0.0009335087,0.0015518898,0.000018451,0.48778892,0.0023075019,0.02424192,0.0070860926],"study_design_scores_gemma":[0.001293391,0.0007905901,0.8433131,0.0004222291,0.00015412916,0.00038664052,0.0021529836,0.0007643955,0.08342507,0.0004748045,0.06612338,0.0006992878],"about_ca_topic_score_codex":0.00033571018,"about_ca_topic_score_gemma":0.00002933313,"teacher_disagreement_score":0.40436384,"about_ca_system_score_codex":0.00004093306,"about_ca_system_score_gemma":0.00017936743,"threshold_uncertainty_score":0.9999666},"labels":[],"label_agreement":null},{"id":"W4400644133","doi":"10.3390/antib13030056","title":"Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data","year":2024,"lang":"en","type":"article","venue":"Antibodies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Atezolizumab; Adverse effect; Medicine; Immune system; Adverse Event Reporting System; Pharmacovigilance; Immunology; Nivolumab; Internal medicine; Oncology; Immunotherapy","score_opus":0.030119052346939075,"score_gpt":0.32354702952838066,"score_spread":0.2934279771814416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400644133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97421294,0.015059018,0.0000094168445,0.00068670197,0.0006268493,0.00032692408,0.0003423173,0.0004157472,0.008320055],"genre_scores_gemma":[0.98145926,0.00626197,0.00007116177,0.00026251646,0.000113703594,0.000007166704,0.0026481668,0.000047704547,0.009128354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850047,0.000055915138,0.0003780484,0.000493528,0.00030805258,0.00026396356],"domain_scores_gemma":[0.9990325,0.000126013,0.000102805694,0.00061515864,0.000058006295,0.000065506414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001313711,0.00024086701,0.00037663587,0.00015936514,0.00011666272,0.000022877337,0.00025154304,0.00008150837,0.00027753005],"category_scores_gemma":[0.000025829122,0.00017139268,0.000105355415,0.0005461443,0.0001398899,0.0002747753,0.00010670727,0.00025895098,0.00014927541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012439767,0.0011259704,0.4944446,0.00083742745,0.030876547,0.0050389105,0.006677955,0.000026000045,0.30521187,0.0010932304,0.10954458,0.032683153],"study_design_scores_gemma":[0.008089609,0.00030125177,0.88623387,0.006661173,0.0013957937,0.00003472933,0.0002930554,0.003150458,0.015610165,0.0005377109,0.07689549,0.00079669413],"about_ca_topic_score_codex":0.0014287696,"about_ca_topic_score_gemma":0.0005006879,"teacher_disagreement_score":0.3917893,"about_ca_system_score_codex":0.00013158636,"about_ca_system_score_gemma":0.00017586653,"threshold_uncertainty_score":0.69891906},"labels":[],"label_agreement":null},{"id":"W4400676936","doi":"10.3390/antib13030057","title":"Humanization of Pan-HLA-DR mAb 44H10 Hinges on Critical Residues in the Antibody Framework","year":2024,"lang":"en","type":"article","venue":"Antibodies","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; Hospital for Sick Children; University of Toronto","funders":"Canadian Light Source; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; National Cancer Institute; Canada Research Chairs; National Institutes of Health; Hospital for Sick Children; Office of Science; National Institute of General Medical Sciences; Canadian Institute for Advanced Research; Argonne National Laboratory; U.S. Department of Energy","keywords":"Paratope; Monoclonal antibody; Antibody; Antigen; Immunogenicity; Complementarity determining region; Human leukocyte antigen; Major histocompatibility complex; Computational biology; Biology; Humanized antibody; Immunology; Cell biology","score_opus":0.04654255567493678,"score_gpt":0.42540966716732165,"score_spread":0.3788671114923849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400676936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9475863,0.010998832,0.0001712693,0.027433766,0.00035383133,0.0003316492,0.00003957188,0.00008900264,0.012995751],"genre_scores_gemma":[0.99428785,0.0027487096,0.0005947268,0.0007605012,0.0004324577,0.000008900334,0.00006307576,0.000025911495,0.0010778836],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9981708,0.00014253515,0.0003528398,0.00032262708,0.00065486785,0.00035633455],"domain_scores_gemma":[0.9979936,0.0014905361,0.000028409888,0.0003105078,0.00012575433,0.00005122402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049729855,0.00019229716,0.00033968306,0.0002877992,0.00013160595,0.00008163584,0.0002088949,0.00013465493,0.00023845752],"category_scores_gemma":[0.00077347364,0.00011655086,0.00013115689,0.00042897355,0.00038498023,0.00011005315,0.00007493655,0.00058832683,0.00012595065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005359104,0.0005861532,0.1408422,0.002378747,0.00016947322,0.0009773065,0.005846061,0.0000055102423,0.014744678,0.8143571,0.012843346,0.0067135254],"study_design_scores_gemma":[0.000616011,0.0022437056,0.8296942,0.0075540277,0.00021444357,0.00022960552,0.0033374492,0.0006991404,0.0291214,0.094991535,0.030727694,0.00057080685],"about_ca_topic_score_codex":0.0002654738,"about_ca_topic_score_gemma":0.00005255882,"teacher_disagreement_score":0.71936554,"about_ca_system_score_codex":0.00002367329,"about_ca_system_score_gemma":0.000075090844,"threshold_uncertainty_score":0.4752806},"labels":[],"label_agreement":null},{"id":"W4400724181","doi":"10.3390/antib13030059","title":"Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database","year":2024,"lang":"en","type":"article","venue":"Antibodies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Adverse effect; CTLA-4; PD-L1; Immune system; Database; Medicine; Immunology; Computer science; Pharmacology; Immunotherapy; T cell","score_opus":0.014978496399803282,"score_gpt":0.2970432694413767,"score_spread":0.2820647730415734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400724181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946833,0.0037750036,0.000015212215,0.00036026334,0.0003881706,0.00028738193,0.00019630072,0.00003211618,0.00026225124],"genre_scores_gemma":[0.9967879,0.002023115,0.00012633273,0.00008674987,0.00006671172,0.000006226474,0.00014389749,0.000020373465,0.0007387093],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99845207,0.00007933801,0.000579405,0.0003178247,0.0003673812,0.00020397051],"domain_scores_gemma":[0.9989812,0.00005867771,0.00019098264,0.0006165231,0.00009014466,0.00006250145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046575943,0.00020169248,0.0005148149,0.0003254963,0.00007485858,0.0000035323394,0.00015015832,0.000078654135,0.00020634217],"category_scores_gemma":[0.000056667992,0.00013481747,0.0004764081,0.000812724,0.00025387495,0.00022685941,0.00013922647,0.0001407646,0.000005623265],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022315835,0.0005646042,0.30915353,0.0012916222,0.0076049464,0.000044758075,0.00403701,0.00003149054,0.66890323,0.00007502849,0.00038216604,0.005680038],"study_design_scores_gemma":[0.0019694474,0.00031497917,0.8296615,0.0018594499,0.0037043213,0.00001990482,0.002639652,0.0010428018,0.15613958,0.00004577947,0.0023443955,0.0002581934],"about_ca_topic_score_codex":0.0014787302,"about_ca_topic_score_gemma":0.0002450619,"teacher_disagreement_score":0.52050793,"about_ca_system_score_codex":0.000049849852,"about_ca_system_score_gemma":0.00010391436,"threshold_uncertainty_score":0.5497697},"labels":[],"label_agreement":null},{"id":"W4412700485","doi":"10.3390/antib14030064","title":"Determination of the Epitopes of Alpha-Glucosidase Anti-Drug Antibodies in Pompe Disease Patient Plasma Samples","year":2025,"lang":"en","type":"article","venue":"Antibodies","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Jewish General Hospital; Fondation De Famille Alvin Segal; Genome Canada; Warren Y. Soper Charitable Trust; McGill University","keywords":"Epitope; Recombinant DNA; Enzyme replacement therapy; Glycogen storage disease type II; Antibody; Enzyme; Antigen; Drug; Virology; Biology; Chemistry; Disease; Molecular biology; Biochemistry; Pharmacology; Immunology; Medicine; Internal medicine; Gene","score_opus":0.016183620632939072,"score_gpt":0.3006729632587627,"score_spread":0.2844893426258236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412700485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415886,0.0025919373,0.000028674825,0.0014246268,0.00014051031,0.0005735924,0.000060929306,0.00001854769,0.0010023135],"genre_scores_gemma":[0.9983432,0.0008530093,0.00032474654,0.000096247124,0.00001380297,0.000014003627,0.00002111525,0.0000124413955,0.00032141947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846673,0.00012085061,0.00046978428,0.00025231077,0.00042995968,0.00026034677],"domain_scores_gemma":[0.9988899,0.00024149276,0.00015289217,0.0004024103,0.000258484,0.00005480358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016770196,0.0001664061,0.00043656578,0.0003388248,0.0000890933,0.000012686231,0.0002075265,0.00004839036,0.00002687834],"category_scores_gemma":[0.00088576355,0.00011552112,0.00016244334,0.00048202364,0.00042328722,0.00011660321,0.00023468163,0.00014359015,0.0000031488987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002514958,0.0004801165,0.95933294,0.0009954594,0.00005447783,0.000032755514,0.0012383652,0.000015206643,0.018577138,0.0007402022,0.0004789321,0.01780293],"study_design_scores_gemma":[0.00087319454,0.00006760801,0.8540856,0.0009538445,0.00006714247,0.0000020441848,0.0009813926,0.0005202922,0.14148003,0.0005006171,0.00036898267,0.00009922887],"about_ca_topic_score_codex":0.00075161067,"about_ca_topic_score_gemma":0.00034093377,"teacher_disagreement_score":0.12290289,"about_ca_system_score_codex":0.000044144126,"about_ca_system_score_gemma":0.00018865317,"threshold_uncertainty_score":0.47108147},"labels":[],"label_agreement":null},{"id":"W4414356495","doi":"10.3390/antib14030080","title":"Development of a Chicken Immunoglobulin Heavy Chain Variable Region (VH) Single-Domain Antibody (sdAb) Against Calsequestrin (CSQ) and Its Application","year":2025,"lang":"en","type":"article","venue":"Antibodies","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Fusion protein; Immunoglobulin light chain; Recombinant DNA; Antibody; Phage display; Protein engineering; Single-chain variable fragment; Alexa Fluor; Protein G; Protein A/G","score_opus":0.012794732614245243,"score_gpt":0.251205336855404,"score_spread":0.23841060424115879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414356495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96684694,0.0122702755,0.016447373,0.00027391533,0.00042484645,0.000658322,0.000028999237,0.00011775751,0.002931559],"genre_scores_gemma":[0.99106866,0.00094017654,0.0052948035,0.00018316518,0.00001694308,0.00004370062,0.00028551044,0.000021531258,0.0021455132],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983311,0.0001312907,0.00065940333,0.00042606628,0.00005156456,0.00040055788],"domain_scores_gemma":[0.99918944,0.00007664062,0.00025401154,0.00034790684,0.00011211282,0.000019900477],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042555924,0.00027710779,0.00049960514,0.00021571868,0.0003838073,0.000023703351,0.00025473384,0.00031023813,0.00001908163],"category_scores_gemma":[0.00007001192,0.00026089992,0.00006419636,0.00028388304,0.0001699554,0.00012339506,0.0002375916,0.00023162412,0.00004653109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013974676,0.0002102377,0.00055221404,0.00012018565,0.00022134447,0.0000022959214,0.00083398697,0.000002411034,0.96091133,0.026154416,0.00015179515,0.010700033],"study_design_scores_gemma":[0.0012679597,0.0001284731,0.0039743097,0.00041977613,0.00004459311,0.00002129818,0.00079829054,0.00002295131,0.9308123,0.0016128597,0.060561184,0.00033601272],"about_ca_topic_score_codex":0.0000717454,"about_ca_topic_score_gemma":0.00002287273,"teacher_disagreement_score":0.06040939,"about_ca_system_score_codex":0.00006323103,"about_ca_system_score_gemma":0.00016184954,"threshold_uncertainty_score":0.9999843},"labels":[],"label_agreement":null}]}